ADMA Biologics (NASDAQ:ADMA) Releases Quarterly Earnings Results, Hits Expectations

ADMA Biologics (NASDAQ:ADMA) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16, FiscalAI reports. ADMA Biologics had a net margin of 32.98% and a return on equity of 39.60%. The company had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same period last year, the firm posted $0.14 EPS. ADMA Biologics’s revenue for the quarter was up 2.0% on a year-over-year basis.

Here are the key takeaways from ADMA Biologics’ conference call:

• ASCENIV momentum accelerated: Second-quarter revenue rose 24% year over year to $102.9 million, with June showing the strongest sequential end-user utilization growth since the first half of 2024. Management attributed the trend to increased physician adoption, new patient starts, broader payer engagement, and supporting real-world evidence.
• Profitability and cash generation improved: Revenue increased 2% year over year to $124.4 million, while gross margin expanded to 69% from 55% and adjusted EBITDA rose 22% to $61.8 million, supported by ASCENIV mix and manufacturing efficiencies.
• BIVIGAM remains under pressure: Although demand and revenue improved sequentially as market conditions stabilized, management still expects BIVIGAM revenue to decline approximately 40%–50% from 2025 levels amid excess standard immunoglobulin supply, discounting, and competitive pressures.
• 2026 guidance was reiterated: ADMA continues to forecast revenue of $530 million–$560 million, adjusted EBITDA of $265 million–$300 million, and adjusted net income of $170 million–$200 million, while stating it remains confident in meeting or exceeding those expectations.
• Capital allocation and pipeline progress continued: The company repurchased approximately 7.1 million shares in the quarter and remains on track for at least $200 million of 2026 buybacks. SG-001 is advancing toward conformance lot production in the second half of 2026 and a planned FDA pre-IND meeting package submission by year-end, with management estimating a potential $300 million–$500 million annual opportunity if approved.

ADMA Biologics Price Performance

ADMA opened at $10.06 on Friday. The company’s 50 day simple moving average is $8.59 and its 200 day simple moving average is $11.32. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. ADMA Biologics has a 1 year low of $7.21 and a 1 year high of $20.46. The stock has a market capitalization of $2.33 billion, a PE ratio of 14.37 and a beta of 0.74.

Insider Buying and Selling

In related news, Director Jerrold B. Grossman purchased 12,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were bought at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the acquisition, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 3.90% of the company’s stock.

Institutional Trading of ADMA Biologics

A number of large investors have recently modified their holdings of ADMA. Cibc World Markets Corp purchased a new stake in shares of ADMA Biologics in the 4th quarter valued at approximately $280,000. Meeder Asset Management Inc. purchased a new position in ADMA Biologics during the 4th quarter worth approximately $191,000. Cibc World Market Inc. grew its position in ADMA Biologics by 31.1% during the 4th quarter. Cibc World Market Inc. now owns 13,499 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 3,201 shares in the last quarter. Virtus Advisers LLC grew its holdings in shares of ADMA Biologics by 318.8% during the third quarter. Virtus Advisers LLC now owns 18,412 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 14,016 shares in the last quarter. Finally, Lido Advisors LLC increased its stake in shares of ADMA Biologics by 10.7% during the 3rd quarter. Lido Advisors LLC now owns 16,478 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 1,599 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ADMA. Zacks Research downgraded ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Raymond James Financial initiated coverage on ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price on the stock. Canaccord Genuity Group cut their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $18.67.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reaffirmed its 2026 revenue guidance of $530 million to $560 million and said it is targeting more than $200 million in share repurchases, signaling management confidence and potential support for the stock. ADMA reiterates 2026 guidance and share repurchase plans
• Positive Sentiment: Second-quarter results showed revenue of $124.4 million, GAAP net income of $37.8 million and adjusted EBITDA of $61.8 million. ASCENIV revenue rose 24% year over year to $102.9 million, while management said BIVIGAM demand and utilization stabilized. ADMA Biologics second-quarter 2026 results
• Neutral Sentiment: Adjusted EPS of $0.16 matched analyst expectations, but revenue of $124.4 million fell slightly short of the $125.3 million consensus estimate. The company attributed the revenue pressure primarily to weakness in BIVIGAM, partly offset by ASCENIV growth. ADMA Q2 earnings and revenue analysis
• Negative Sentiment: Several law firms publicized a securities-fraud class action against ADMA and certain executives. The allegations reportedly involve financial condition, revenue recognition, inventory distribution and business practices; the claims have not been proven. Investors in the August 9, 2024–March 25, 2026 class period face an August 10 lead-plaintiff deadline. ADMA securities-fraud class-action notice
• Negative Sentiment: Zacks Research downgraded ADMA from “Hold” to “Strong Sell,” adding pressure to the investment narrative despite the company’s maintained guidance.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.